The Canadian Generic Pharmaceutical Association (CGPA) has elected Jeff Watson, president of global generics at Apotex, as chair of CGPA, and Larry MacGirr, chief operating officer of Pharmascience, as vice chair of CGPA.
In a CGPA statement, Watson said that CGPA’s focus will remain on working with Canada’s provinces and territories to ensure that the national pricing framework signed between the Council of Federation (CoF) and CGPA provides a stable, predictable pricing and reimbursement environment for generic drugs. “The pricing environment in Canada has changed dramatically over the past eight years. This has provided hundreds of millions of dollars in additional savings to our health-care system,” said Watson in the statement. “These changes have, however, put significant strain on the generic pharmaceutical supply chain in Canada, including pharmacies, distributors and manufacturers.”
Watson also stated that there remain significant challenges for the industry in working with federal and international regulators to ensure that rapidly evolving regulatory requirements do not threaten the ongoing supply of generic pharmaceutical products in the Canadian market and the industry’s ability to research, develop and manufacture products in Canada.“Patient safety is of paramount importance. We must work with regulators to ensure that the sweeping changes being implemented in Canada and globally are done so in a manner that does not threaten patient access and safety,” Watson added.
Mr. Watson also said that CGPA will also be focusing on ensuring that Canada is a viable market for the production and sale of biosimilar treatments.
Mr. Watson joined Apotex in 1993 and, over the last 20 years, has held various positions within Apotex. He was appointed president of Global Generics at Apotex in March 2015.
Larry MacGirr has been with Pharmascience for the past four years. Prior to joining Pharmascience, Mr. MacGirr spent 17 years in the pharmaceutical over-the-counter and medical device businesses in the United States and Canada.
Source: Canadian Generic Pharmaceutical Association